From August 23 to 24, 2024, Libofei® ^, a brand of Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd. (hereinafter referred to as "Suzhou Chung-Hwa Chemical & Pharmaceutical"), appeared at the 2024 Hubei Digestive Disease Annual Conference hosted by the Gastroenterology Branch of the Hubei Medical Association. The 2024 Hubei Digestive Disease Annual Conference was grandly held in Wuhan.

The 2024 Hubei Digestive Academic Annual Conference closely revolves around hot topics in the field of digestion. The content of the conference is rich and diverse without losing depth, covering many important sub-fields in the field of digestion, such as digestive system tumors, inflammatory bowel disease, functional gastrointestinal disease, liver disease, biliary and pancreatic diseases, and the latest advances in endoscopic diagnosis and treatment.

The conference also carefully designed several sections, including the domestic well-known experts forum, special reports in the sub-venues, youth forum and paper results display, etc., aiming to provide a comprehensive and free learning and communication platform for each medical participant. In addition, this conference also invited many well-known experts in the field of digestion in China, and these experts gave wonderful academic reports on site, sharing their front-line research results and clinical experience in the field of digestion.

Libofei ^® calcium polycarbophil is the star product of Suzhou Chung-Hwa Chemical & Pharmaceutical, and its main ingredient is calcium polycarbophil. Calcium polycarbophil is a bulk laxative and a basic drug for step-by-step treatment of constipation (source: World Gastroenterology Organization Practice Guidelines), and is also a first-line treatment drug clearly recommended by relevant domestic and foreign guidelines. After decalcification under gastric acid conditions, calcium polycarbophil can form a hydrophilic gel in the intestine, participate in stool formation, increase the water content and volume of stool, make the stool soft and easy to pass, and not absorbed into the blood, with high safety in clinical application. The emergence of Libofei ^® calcium polycarbophil has brought a new option for safe and effective constipation treatment to the clinic, and has provided clinicians with a new treatment plan for constipation.

Suzhou Chung-Hwa Chemical & Pharmaceutical has always been committed to promoting the advancement of clinical diagnosis and treatment technologies for digestive diseases. In the future, Suzhou Chung-Hwa Chemical & Pharmaceutical will continue to be committed to innovation and development in the field of digestive diseases in my country.